Sculptra Description

Each vial of dry powder contains: Poly-L-lactic acid 150 mg.
Sculptra is a poly-L-lactic acid implant in the form of a sterile non-pyrogenic suspension, which is reconstituted from a sterile dry powder by the addition of sterile water for injection. This suspension contains microparticles of poly-L-lactic acid, a crystalline form of polylactic acid. Poly-L-lactic acid is a biocompatible, biodegradable, synthetic polymer from the alpha-hydroxy-acid family.
Sculptra dry powder is supplied after aseptic filtration sterilisation in a sterile elongated clear glass vial with an aluminium ring at one end, which is hermetically sealed by a rubber bung, covered by a flip-off cap.
Sculptra dry powder is reconstituted with 5-8 ml of sterile water for injection to form a sterile non-pyrogenic suspension. As an optional means to provide pain relief during the injection procedure, an additional 1 ml of sterile 2% (20 mg/ml) lidocaine solution may be added to the vial of reconstituted product prior to injection for a final volume of 6-9 ml (refer to Treatment procedure under Cautions for Usage).
Excipients/Inactive Ingredients: Each vial of dry powder contains: Sodium carboxymethylcellulose 90 mg; Non-pyrogenic mannitol 127.5 mg.